Trial · NCT00229658
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Incidence of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period | 0-3 months | Intent-to-Treat | Incidence (%) | NUMBER |
| PRIMARY | Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Adjustment Period | 0-3 months | Intent-to-Treat | Events per patient year | NUMBER |
| SECONDARY | The Incidence of Patient-Ascertained Severe Hypoglycemia (PASH) During the Steady State Period | >3-6 months | Intent-to-Treat, number analyzed includes patients still enrolled in the study during the steady-state period (3-6 months) | Incidence (%) | NUMBER |
| SECONDARY | The Annual Event Rate of Patient-Ascertained Severe Hypoglycemia (PASH) During the Steady State Period | >3-6 months | Intent-to-Treat, number analyzed includes patients still enrolled in the study during the steady-state period (3-6 months) | Events per patient year | NUMBER |
| SECONDARY | Incidence of Medically Assisted Severe Hypoglycemia (MASH) During the Adjustment Period | 0-3 months | Intent-to-Treat. | Incidence (%) | NUMBER |
| SECONDARY | The Annual Event Rate of Medically Assisted Severe Hypoglycemia (MASH) During the Adjustment Period | 0-3 months | Intent-to-Treat | Events per patient year | NUMBER |
| SECONDARY | Incidence of Medically Assisted Severe Hypoglycemia (MASH) During the Steady State Period | >3-6 months | Intent-to-Treat, number analyzed includes patients still enrolled in the study during the steady-state period (3-6 months) | Incidence (%) | NUMBER |
| SECONDARY | Annual Event Rate of Medically Assisted Severe Hypoglycemia (MASH) During the Steady State Period | >3-6 months | Intent-to-Treat, number analyzed includes patients still enrolled in the study during the steady-state period (3-6 months) | Events per patient year | NUMBER |
| SECONDARY | Change in HbA1c From Baseline at Month 3 | 3 months | Intent-to-Treat, patients who discontinue SYMLIN 7 or more days prior to a site visit are not included in the analyses | percent | MEAN |
| SECONDARY | Change in HbA1c From Baseline at Month 6 | 6 months | Intent-to-Treat, patients who discontinue SYMLIN 7 or more days prior to a site visit are not included in the analyses | percent | MEAN |
| SECONDARY | Change in Body Weight From Baseline at Month 3 | 3 months | Intent-to-Treat, patients who discontinue SYMLIN 7 or more days prior to a site visit are not included in the analyses | kg | MEAN |
| SECONDARY | Change in Body Weight From Baseline at Month 6 | 6 months | Intent-to-Treat, patients who discontinue SYMLIN 7 or more days prior to a site visit are not included in the analyses | kg | MEAN |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00229658/outcomes